Success Metrics

Clinical Success Rate

71.4%

Based on 15 completed trials

Completion Rate

71%(15/21)

Active Trials

0(0%)

Results Posted

40%(6 trials)

Terminated

6(26%)

Phase Distribution

Ph phase_1

52%

Ph phase_2

43%

Ph phase_3

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution23 total trials

Phase 1Safety & dosage

12(52.2%)

Phase 2Efficacy & side effects

10(43.5%)

Phase 3Large-scale testing

1(4.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

68.2%

15 of 22 finished

Non-Completion Rate

31.8%

7 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(15)

Terminated(7)

Other(1)

Detailed Status

Completed15

Terminated6

Withdrawn1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

71.4%

Most Advanced

Phase 3

Trials by Phase

Phase 112 (52.2%)

Phase 210 (43.5%)

Phase 31 (4.3%)

Trials by Status

withdrawn14%

unknown14%

terminated626%

completed1565%

Recent Activity

0 active trials

Showing 5 of 23

completedphase_1

Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma

NCT01165333

completedphase_1

Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer

NCT00884598

completedphase_2

Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy

NCT00679354

withdrawnphase_2

Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)

NCT01782976

terminatedphase_2

Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme

NCT00112866

View all 23 trials

Clinical Trials (23)

Showing 20 of 23 trialsScroll for more

NCT01165333Phase 1

Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma

Completed

NCT00884598Phase 1

Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer

Completed

NCT00679354Phase 2

Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy

Completed

NCT01782976Phase 2

Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)

Withdrawn

NCT00112866Phase 2

Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme

Terminated

NCT00842712Phase 2

Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)

Completed

NCT00121238Phase 2

Cilengitide in Treating Patients With Prostate Cancer

Completed

NCT01276496Phase 1

Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

Completed

NCT00085254Phase 1

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed

NCT01517776Phase 2

Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents

Terminated

NCT01122888Phase 1

Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme

Terminated

NCT00979862Phase 1

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

Completed

NCT00689221Phase 3

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status

Completed

NCT00004258Phase 1

EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer